Stage III NSCLC: When to Start Durvalumab

PACIFIC-6: Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC | CRSFПодробнее

Maintenance immunotherapy in unrespectable stage III NSCLC Speaker: Dr. Turki Al Fayea Day 2Подробнее

Dr Srinivas KG - Maintenance Therapy In Locally Advanced Stage III NSCLC DurvalumabПодробнее

Treating for Stage III NSCLC After Progression on DurvalumabПодробнее

Refining which patients benefit from consolidation durvalumab for stage III unresectable NSCLCПодробнее

Durvalumab in Stage III NSCLC Based on Performance StatusПодробнее

Panel Discussion | Dr Randeep Singh | Durvalumab in Stage III NSCLCПодробнее

Dr Arun Chandrasekharan | Durvalumab in stage III NSCLC Increasing hope for cureПодробнее

[lung]The role of durvalumab in patients with stage 3 lung cancer in a real hospitalПодробнее

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLCПодробнее

FDA Approval of Durvalumab for Stage III Unresectable NSCLCПодробнее

Immunotherapy in Stage III NSCLC: Practice-Changing Results of PACIFIC Trial (BMIC-006)Подробнее

Durvalumab improves PFS in stage III lung cancerПодробнее

PACIFIC trial of durvalumab for stage III NSCLCПодробнее

Durvalumab: A new option for stage III NSCLC patients? | Davey DanielПодробнее

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLCПодробнее

Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Standard of Care? (BMIC-024)Подробнее